Abstract:Choroidal neovascularization (CNV) is the leading cause of vision loss in many blinding diseases, but current antiangiogenic therapies with invasively intravitreal injection suffer from poor patient compliance and a rate of devastating ocular complications. Here, we develop an alternative antiangiogenic agent based on hybrid cell-membrane-cloaked nanoparticles for noninvasively targeted treatment of CNV. The retinal endotheliocyte membrane coating provides as-fabricated nanoagents with homotypic targeting capability and binding ability to the vascular endothelial growth factor. The fusion of red blood cell membranes protects the hybrid membrane-coated nanoparticles from phagocytosis by macrophages. In a laser-induced wet age-related macular degeneration mouse model, a significantly enhanced accumulation is observed in CNV regions after intravenous delivery of the hybrid membrane-coated nanoparticles. Moreover, an excellent therapeutic efficacy is achieved in reducing the leakage and area of CNV. Overall, the biomimetic antiangiogenic nanoagents provide an effective approach for noninvasive treatment of CNV.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.1c00680?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.1c00680</a>.Confirmation of complete hybrid membrane coating onto PLGA nanoparticle cores (Figure S1); long-term stability of [RBC-REC]NPs (Figure S2); self-recognition capability of RECNPs and [RBC-REC]NPs in vitro (Figure S3); targeting affinity to angiogenic endothelial cells in vitro (Figure S4); macrophage uptake of nanoparticles in vitro (Figure S5); biodistribution of nanoparticles in vivo (Figure S6); representative fundus photographs in the day 7 (Figure S7); active-targeting capability of [RBC-REC]NPs in CNV (Figure S8); ability of [RBC-REC]NPs in suppressing endothelial cell migration in vitro (Figure S9); cytotoxic assessment to different ocular cells (Figure S10); biosafety assessment of as-fabricated nanoparticles (Figure S11) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.1c00680/suppl_file/nn1c00680_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Drug Delivery Nanoparticles: Toxicity Comparison in Retinal Pigment Epithelium and Retinal Vascular Endothelial Cells

Nanoparticles in the Ocular Drug Delivery

Recent Advances and Prospects for Lipid-Based Nanoparticles As Drug Carriers in the Treatment of Human Retinal Diseases

The toxic effects of polystyrene microplastic/nanoplastic particles on retinal pigment epithelial cells and retinal tissue

Safety and toxicity of nanomaterials for ocular drug delivery applications

PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers

Safety Evaluation of Poly(lactic-Co-glycolic Acid)/poly(lactic-Acid) Microspheres Through Intravitreal Injection in Rabbits

Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure

Intraocular Fate of Polycaprolactone Nanoparticles Administered Via Intravitreal and Various Periocular Routes: Bioimaging of Integral Nanoparticles Using Environment-Sensitive Fluorophores

Evaluation of Topical and Subconjunctival Injection of Hyaluronic Acid-Coated Nanoparticles for Drug Delivery to Posterior Eye

The effect of nanoparticle properties, detection method, delivery route and animal model on poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats

Differences in toxicity induced by the various polymer types of nanoplastics on HepG2 cells

Reexamining the effects of drug loading on the in vivo performance of PEGylated liposomal doxorubicin

Polyethylene Glycol-Modified Pigment Epithelial-Derived Factor: New Prospects for Treatment of Retinal Neovascularization

Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery

The effects of PEGylation on LNP based mRNA delivery to the eye

Nanoparticle‐based sustained drug delivery for the treatment of ocular neovascular diseases

Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery

Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury

Are PAMAM dendrimers safe for ocular applications? -- Toxicological evaluation in ocular cells and intraocular tissues

Targeted Noninvasive Treatment of Choroidal Neovascularization by Hybrid Cell-Membrane-Cloaked Biomimetic Nanoparticles